Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Makoto Chuma

Showing results (11-20 of 118) with videos related to

Pageof 12
Sort By:
Journal of Medical Ultrasonics (2001)|January 25, 2018
Fusion imaging with contrast-enhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepatocellular carcinomas with iso-echoic or unclear margins on conventional ultrasonographyShuhei Nishigori, Kazushi Numata, Kuniyasu Irie, et al.
World Journal of Clinical Cases|July 2, 2020
Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reportsSatoshi Komiyama, Kazushi Numata, Satoshi Moriya, et al.
The Keio Journal of Medicine|July 13, 2004
Expression profiling in hepatocellular carcinoma with intrahepatic metastasis: identification of high-mobility group I(Y) protein as a molecular marker of hepatocellular carcinoma metastasisMakoto Chuma, Norihisa Saeki, Yoshiya Yamamoto, et al.
Antiviral Therapy|July 7, 2009
Immunological and mutagenic actions of ribavirin monotherapy preceding combination therapy with interferon for patients with chronic hepatitis CKoji Ogawa, Shuhei Hige, Mitsuru Nakanishi, et al.
Medicine|July 25, 2020
Therapeutic effects of regorafenib after sorafenib monotherapy with advanced hepatocellular carcinoma including Child-Pugh classification B: A retrospective observational studySatoshi Komiyama, Kazushi Numata, Katsuaki Ogushi, et al.
Hepatology (Baltimore, Md.)|December 25, 2002
Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinomaMakoto Chuma, Michiie Sakamoto, Ken Yamazaki, et al.
Journal of Gastroenterology and Hepatology|October 16, 2008
8-Hydroxy-2'-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infectionMakoto Chuma, Shuhei Hige, Mitsuru Nakanishi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 29, 2011
Clinicopathological significance of nuclear factor-κB activation in hepatocellular carcinomaHideki Yokoo, Jun Yasuda, Kazuaki Nakanishi, et al.
Gastroenterology Research and Practice|July 19, 2017
Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival PostprogressionMasaaki Kondo, Kazushi Numata, Koji Hara, et al.
European Journal of Gastroenterology & Hepatology|February 1, 2022
Impact of psoas muscle index assessed by a simple measurement method on tolerability and duration of continued treatment with sorafenib in hepatocellular carcinoma patientsKatsuaki Ogushi, Makoto Chuma, Kazushi Numata, et al.
Pageof 12

Showing results (11-20 of 118) with videos related to

Sort By:
Pageof 12
Journal of Medical Ultrasonics (2001)|January 25, 2018
Fusion imaging with contrast-enhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepatocellular carcinomas with iso-echoic or unclear margins on conventional ultrasonographyShuhei Nishigori, Kazushi Numata, Kuniyasu Irie, et al.
World Journal of Clinical Cases|July 2, 2020
Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reportsSatoshi Komiyama, Kazushi Numata, Satoshi Moriya, et al.
The Keio Journal of Medicine|July 13, 2004
Expression profiling in hepatocellular carcinoma with intrahepatic metastasis: identification of high-mobility group I(Y) protein as a molecular marker of hepatocellular carcinoma metastasisMakoto Chuma, Norihisa Saeki, Yoshiya Yamamoto, et al.
Antiviral Therapy|July 7, 2009
Immunological and mutagenic actions of ribavirin monotherapy preceding combination therapy with interferon for patients with chronic hepatitis CKoji Ogawa, Shuhei Hige, Mitsuru Nakanishi, et al.
Medicine|July 25, 2020
Therapeutic effects of regorafenib after sorafenib monotherapy with advanced hepatocellular carcinoma including Child-Pugh classification B: A retrospective observational studySatoshi Komiyama, Kazushi Numata, Katsuaki Ogushi, et al.
Hepatology (Baltimore, Md.)|December 25, 2002
Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinomaMakoto Chuma, Michiie Sakamoto, Ken Yamazaki, et al.
Journal of Gastroenterology and Hepatology|October 16, 2008
8-Hydroxy-2'-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infectionMakoto Chuma, Shuhei Hige, Mitsuru Nakanishi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 29, 2011
Clinicopathological significance of nuclear factor-κB activation in hepatocellular carcinomaHideki Yokoo, Jun Yasuda, Kazuaki Nakanishi, et al.
Gastroenterology Research and Practice|July 19, 2017
Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival PostprogressionMasaaki Kondo, Kazushi Numata, Koji Hara, et al.
European Journal of Gastroenterology & Hepatology|February 1, 2022
Impact of psoas muscle index assessed by a simple measurement method on tolerability and duration of continued treatment with sorafenib in hepatocellular carcinoma patientsKatsuaki Ogushi, Makoto Chuma, Kazushi Numata, et al.
Pageof 12